The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
The user has been using a hair regrowth regimen for 9-10 months, including topical finasteride and minoxidil, various oils, and supplements like multivitamins and omega-3. They observed fine hairs returning and a change in scalp texture after adding cinnamon oil, questioning if this indicates positive hair regrowth.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.
The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.
Hair loss and potential treatments, primarily focusing on Finasteride and Minoxidil. Other solutions discussed include PRP, dermarolling, LLP, and scalp tension relief.
A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
Vitamin D tests like D2, D3, and 25-hydroxyvitamin D are discussed before starting hair treatment. Vitamin D can be obtained from food, but overdose has side effects.
A user shared a discount code for RU58841 from Anagen Inc, which some users find effective for hair loss without side effects. Another user expressed skepticism about the safety of RU58841 due to limited research.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
Caffeine might raise stress hormones, potentially worsening hair loss. Telogen effluvium is often misattributed to minor stressors rather than significant life events.
OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.
Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.
The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.
The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.
Topical diazoxide may be a promising hair regrowth treatment, especially for those who don't respond to minoxidil, as it activates potassium channels without needing sulfation. It appears safe for topical use, avoiding systemic effects seen in oral use.
The user saw significant hair regrowth using topical minoxidil and finasteride, even on areas not directly treated. They used local Algerian products with 5% minoxidil and 0.1% finasteride and reported no side effects.
The conversation is about finding an alternative hair growth stimulator for someone who cannot use Minoxidil due to heart issues. The person is currently using topical dutasteride, azelaic acid, and occasional microneedling, and is considering options like retinyl palmitate, latanoprost, certizine, or tadalafil.
A user found a successful hair loss treatment using a combination of finasteride, dutasteride, minoxidil, and RU58841. They plan to switch to a purely topical regimen with finasteride, RU58841, and minoxidil.
UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.